{"id":7351,"date":"2025-03-24T11:53:19","date_gmt":"2025-03-24T10:53:19","guid":{"rendered":"https:\/\/www.substipharm.com\/comunicado-de-prensa\/"},"modified":"2025-03-24T11:53:21","modified_gmt":"2025-03-24T10:53:21","slug":"comunicado-de-prensa","status":"publish","type":"page","link":"https:\/\/www.substipharm.com\/es\/comunicado-de-prensa\/","title":{"rendered":"Comunicado de prensa"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"7351\" class=\"elementor elementor-7351 elementor-1988\" data-elementor-post-type=\"page\">\n\t\t\t\t\t\t<section class=\"has_eae_slider elementor-section elementor-top-section elementor-element elementor-element-6aea33a elementor-section-height-min-height elementor-section-items-stretch elementor-section-content-middle elementor-section-boxed elementor-section-height-default\" data-eae-slider=\"60649\" data-id=\"6aea33a\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t\t<div class=\"elementor-background-overlay\"><\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-no\">\n\t\t\t\t\t<div class=\"has_eae_slider elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-35ef187\" data-eae-slider=\"17333\" data-id=\"35ef187\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-1d0e288 elementor-widget elementor-widget-heading\" data-id=\"1d0e288\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Comunicado de prensa<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"has_eae_slider elementor-section elementor-top-section elementor-element elementor-element-c18b97f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-eae-slider=\"70875\" data-id=\"c18b97f\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"has_eae_slider elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-b55f407\" data-eae-slider=\"51000\" data-id=\"b55f407\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section class=\"has_eae_slider elementor-section elementor-inner-section elementor-element elementor-element-8976bdf elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-eae-slider=\"61963\" data-id=\"8976bdf\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"has_eae_slider elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-3edbf40\" data-eae-slider=\"1412\" data-id=\"3edbf40\" data-element_type=\"column\" data-e-type=\"column\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-5591bb7 elementor-widget elementor-widget-text-editor\" data-id=\"5591bb7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Substipharm adquiere IMOJEV\u00ae SUBSTIPHARM se enorgullece de anunciar que ha llegado a un acuerdo para adquirir la vacuna contra la Encefalitis Japonesa IMOJEV\u00ae de Sanofi por una cantidad no revelada. IMOJEV\u00ae est\u00e1 indicada para la prevenci\u00f3n de la Encefalitis Japonesa tanto en adultos como en ni\u00f1os, y actualmente se comercializa en Australia, Brunei, Camboya, Hong Kong, Indonesia, Malasia, Myanmar, Filipinas, Taiw\u00e1n, Tailandia, Singapur, Corea del Sur, Sri Lanka y Vietnam. Como empresa privada con sede en Francia, SUBSTIPHARM no s\u00f3lo dedicar\u00e1 todos sus esfuerzos a consolidar la cuota de mercado de IMOJEV\u00ae en sus territorios actuales, sino que tambi\u00e9n realizar\u00e1 fuertes inversiones para ampliar la disponibilidad de esta vacuna a escala mundial.  <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Comunicado de prensa Substipharm adquiere IMOJEV\u00ae SUBSTIPHARM se enorgullece de anunciar que ha llegado a un acuerdo para adquirir la vacuna contra la Encefalitis Japonesa IMOJEV\u00ae de Sanofi por una cantidad no revelada. IMOJEV\u00ae est\u00e1 indicada para la prevenci\u00f3n de la Encefalitis Japonesa tanto en adultos como en ni\u00f1os, y actualmente se comercializa en Australia, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-7351","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Comunicado de prensa - Substipharm<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.substipharm.com\/es\/comunicado-de-prensa\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Comunicado de prensa - Substipharm\" \/>\n<meta property=\"og:description\" content=\"Comunicado de prensa Substipharm adquiere IMOJEV\u00ae SUBSTIPHARM se enorgullece de anunciar que ha llegado a un acuerdo para adquirir la vacuna contra la Encefalitis Japonesa IMOJEV\u00ae de Sanofi por una cantidad no revelada. IMOJEV\u00ae est\u00e1 indicada para la prevenci\u00f3n de la Encefalitis Japonesa tanto en adultos como en ni\u00f1os, y actualmente se comercializa en Australia, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.substipharm.com\/es\/comunicado-de-prensa\/\" \/>\n<meta property=\"og:site_name\" content=\"Substipharm\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-24T10:53:21+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.substipharm.com\/es\/comunicado-de-prensa\/\",\"url\":\"https:\/\/www.substipharm.com\/es\/comunicado-de-prensa\/\",\"name\":\"Comunicado de prensa - Substipharm\",\"isPartOf\":{\"@id\":\"https:\/\/www.substipharm.com\/es\/#website\"},\"datePublished\":\"2025-03-24T10:53:19+00:00\",\"dateModified\":\"2025-03-24T10:53:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.substipharm.com\/es\/comunicado-de-prensa\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.substipharm.com\/es\/comunicado-de-prensa\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.substipharm.com\/es\/comunicado-de-prensa\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.substipharm.com\/es\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Comunicado de prensa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.substipharm.com\/es\/#website\",\"url\":\"https:\/\/www.substipharm.com\/es\/\",\"name\":\"Substipharm\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.substipharm.com\/es\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.substipharm.com\/es\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.substipharm.com\/es\/#organization\",\"name\":\"Substipharm\",\"url\":\"https:\/\/www.substipharm.com\/es\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.substipharm.com\/es\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.substipharm.com\/wp-content\/uploads\/2021\/08\/fichier-1@2x.png\",\"contentUrl\":\"https:\/\/www.substipharm.com\/wp-content\/uploads\/2021\/08\/fichier-1@2x.png\",\"width\":1446,\"height\":219,\"caption\":\"Substipharm\"},\"image\":{\"@id\":\"https:\/\/www.substipharm.com\/es\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Comunicado de prensa - Substipharm","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.substipharm.com\/es\/comunicado-de-prensa\/","og_locale":"es_ES","og_type":"article","og_title":"Comunicado de prensa - Substipharm","og_description":"Comunicado de prensa Substipharm adquiere IMOJEV\u00ae SUBSTIPHARM se enorgullece de anunciar que ha llegado a un acuerdo para adquirir la vacuna contra la Encefalitis Japonesa IMOJEV\u00ae de Sanofi por una cantidad no revelada. IMOJEV\u00ae est\u00e1 indicada para la prevenci\u00f3n de la Encefalitis Japonesa tanto en adultos como en ni\u00f1os, y actualmente se comercializa en Australia, [&hellip;]","og_url":"https:\/\/www.substipharm.com\/es\/comunicado-de-prensa\/","og_site_name":"Substipharm","article_modified_time":"2025-03-24T10:53:21+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.substipharm.com\/es\/comunicado-de-prensa\/","url":"https:\/\/www.substipharm.com\/es\/comunicado-de-prensa\/","name":"Comunicado de prensa - Substipharm","isPartOf":{"@id":"https:\/\/www.substipharm.com\/es\/#website"},"datePublished":"2025-03-24T10:53:19+00:00","dateModified":"2025-03-24T10:53:21+00:00","breadcrumb":{"@id":"https:\/\/www.substipharm.com\/es\/comunicado-de-prensa\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.substipharm.com\/es\/comunicado-de-prensa\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.substipharm.com\/es\/comunicado-de-prensa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.substipharm.com\/es\/"},{"@type":"ListItem","position":2,"name":"Comunicado de prensa"}]},{"@type":"WebSite","@id":"https:\/\/www.substipharm.com\/es\/#website","url":"https:\/\/www.substipharm.com\/es\/","name":"Substipharm","description":"","publisher":{"@id":"https:\/\/www.substipharm.com\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.substipharm.com\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.substipharm.com\/es\/#organization","name":"Substipharm","url":"https:\/\/www.substipharm.com\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.substipharm.com\/es\/#\/schema\/logo\/image\/","url":"https:\/\/www.substipharm.com\/wp-content\/uploads\/2021\/08\/fichier-1@2x.png","contentUrl":"https:\/\/www.substipharm.com\/wp-content\/uploads\/2021\/08\/fichier-1@2x.png","width":1446,"height":219,"caption":"Substipharm"},"image":{"@id":"https:\/\/www.substipharm.com\/es\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.substipharm.com\/es\/wp-json\/wp\/v2\/pages\/7351","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.substipharm.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.substipharm.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.substipharm.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.substipharm.com\/es\/wp-json\/wp\/v2\/comments?post=7351"}],"version-history":[{"count":1,"href":"https:\/\/www.substipharm.com\/es\/wp-json\/wp\/v2\/pages\/7351\/revisions"}],"predecessor-version":[{"id":7353,"href":"https:\/\/www.substipharm.com\/es\/wp-json\/wp\/v2\/pages\/7351\/revisions\/7353"}],"wp:attachment":[{"href":"https:\/\/www.substipharm.com\/es\/wp-json\/wp\/v2\/media?parent=7351"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}